Ai Hirota1, Haruka Izumi1, Daisuke Nagase1, Hirofumi Irita1, Akiko Shibuya1, Yurika Mitsui1, Motohiro Katoh1, Yasunobu Kuraishi1, Kazuho Arai2, Kazuhiko Natori1 (1.Division of Hematology and Oncology, Toho University Medical Center,Tokyo,Japan, 2.Toho University Faculty of Nursing)
Session information
Poster Session
Sun. Oct, 14
Poster Session 3-20 DLBCL: Clinical practice
Sun. Oct 14, 2018 1:00 PM - 1:40 PM Poster2 (Osaka International Convention Center, 5F Main Foyer)
Chair: Shigeru Kusumoto (Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences)
Shoko Marshall1, Noriko Nishimura2, Anna Nishihara2, Norihito Inoue2, Yoshiharu Kusano2, Yuko Mishima2, Masahiro Yokoyama2, Kiyohiko Hatake3, Yasuhito Terui2 (1.Department of Medicine, Tokyo Women's Medical University Medical Center East, 2.Hematology Oncology, The Cancer Institute Hospital of JFCR, 3.Hematology, International University of Health and Welfare, Mita Hospital)
Jeng-Shiun Du1, Hui-Hua Hsiao1,3,4 (1.Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2.Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 3.Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 4.Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan)
[PS3-20-4] Clinical outcomes of addition of high dose methotrexate and cytarabine in DLBCL treatment
Chee Chean Dang1,2,3, Yong Khee Guan2, Chee Ping Chong3 (1.Pharmacy (Hematology) Hospital Melaka, Melaka, Malaysia, 2.Pantai Hospital, Ayer Keroh, Melaka, Malaysia, 3.Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University of Science Malaysia (USM), Penang, Malaysia)
Sayidkhujabek G'olib O'g'li Hoshimov (Hematology, Tashkent Medical Academy, Tashkent, Republic of Uzbekistan)
Ho-Young Yhim1, Sung Kyun Yim1, Yeon-Hee Han2, Myung-Hee Sohn2, Eun-Kee Song1, Chang-Yeol Yim1, Hee Sun Kim3, Jae-Yong Kwak1 (1.Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea, 2.Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea, 3.College of Nursing, Chonbuk National University, Jeonju, Republic of Korea)
Hee Sang Hwang1, Dok Hyun Yoon2, Jung Yong Hong2, Chan-Sik Park1, Yoon Se Lee3, Young Hyeh Ko4, Seok Jin Kim5, Won Seog Kim5, Cheolwon Suh2, Jooryung Huh1 (1.Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 2.Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 3.Department of Otorhinolaryngology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 4.Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 5.Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea)
Man Fai Law (Departmetn of Medicine, Prince of Wales Hospital, Shatin, Hong Kong)